杭州奥泰生物技术股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported a total revenue of 911.30 million RMB for the year 2025, reflecting a growth of 5.16% compared to the previous year, but net profit decreased by 27.83% due to various cost pressures and increased expenses [2][3]. Financial Performance and Condition - The company achieved total revenue of 911.30 million RMB, a 5.16% increase year-on-year - Net profit attributable to shareholders was 218.28 million RMB, down 27.83% from the previous year - Net profit excluding non-recurring gains and losses was 155.25 million RMB, a decline of 34.64% compared to the previous year - Total assets at the end of the reporting period were 4,248.62 million RMB, up 1.50% from the beginning of the period - Shareholders' equity attributable to the parent company was 3,944.50 million RMB, an increase of 1.57% from the beginning of the period [2]. Factors Affecting Performance - The company maintained competitive advantages in R&D innovation, product quality, and customer service, which helped to expand sales channels and increase customer sales volume - Increased investment in new technology platforms and efforts in domestic and international market registrations led to higher R&D and sales costs - Additional factors impacting profit included increased operating costs due to U.S. tariffs, foreign exchange losses from currency fluctuations, reduced interest income, and increased asset depreciation [2][3]. Significant Changes in Financial Metrics - Despite a revenue increase of 5.16%, the overall profitability was pressured by declining product prices, rising sales, management, and R&D expenses, as well as increased financial costs - Key financial metrics such as operating profit, total profit, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses all saw declines of 27.72%, 28.36%, 27.83%, and 34.64% respectively compared to the previous year [3].